Development of Meningococcal Conjugate Vaccines by GSK
Author Information
Author(s): Jacqueline M. Miller, Narcisa Mesaros, Marie Van Der Wielen, Yaela Baine
Primary Institution: GlaxoSmithKline Biologicals
Hypothesis
Can new conjugate vaccines effectively protect against meningococcal diseases in infants and young children?
Conclusion
The study demonstrates that the meningococcal conjugate vaccines developed by GSK are highly immunogenic and have acceptable safety profiles.
Supporting Evidence
- The vaccines were shown to be highly immunogenic.
- Clinically acceptable safety profiles were observed.
- Vaccination programs have been successfully implemented in various countries.
- Conjugate vaccines induce immune memory and higher bactericidal titres.
Takeaway
This study shows that new vaccines can help protect babies and young kids from serious infections caused by bacteria that can lead to meningitis.
Methodology
The vaccines were studied in randomized, controlled clinical trials evaluating immunogenicity, antibody persistence, immune memory, reactogenicity, and safety.
Potential Biases
Potential conflicts of interest due to authors' affiliations with GlaxoSmithKline.
Limitations
The study's findings may not be generalizable to all populations due to regional differences in meningococcal disease incidence.
Participant Demographics
The study involved infants and young children, particularly in high-risk regions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website